Phage Futures 2022

Translating phage-based applications into clinically and commercially viable therapeutics

The leading platform accelerating the translation of bacteriophage research into safe & effective clinically, regulatory & commercially viable therapeutics and tangible commercial solutions

VIEW THE AGENDA
Boston, USA
16-17 November, 2022

“I thought the meeting was well put together with a good variety of presenters from academia, government and industry. I would courage other phage experts to attend future meetings”

Catherine Loc-Carrillo, University of Utah

“It provided a chance to hear about the current progress and challenges in phage therapy. It also provided me with a chance to discuss the resources NIAID has to offer to help those working to develop phage therapy.”

Joseph Campbell, NIH

Why Attend

Phage therapies have shown promise in compassionate use, but limited success of double blind randomised controlled trials has slowed progression through the clinic. Join us at Phage Futures US 2022 to stay up-to-date with the latest techniques progressing phage technologies into commercially viable products that will improve human and animal health worldwide.

Explore key developments in clinical trial design to progress medicinal phage therapeutics to the clinic, genetic editing to increase functionality, the emergence of lytic technologies, and alternative applications of phage technologies outside of human health. Alongside in-depth case study presentations, join the conversation through interactive panel discussions on key challenges within the space – including attracting public & private support to efficiently finance phage-based therapeutics, evaluating approaches to phage sensitivity testing, and leveraging AI & synthetic biology to create predictive models.

Bringing together leading experts from biotech, pharma and academia, and co-located with Microbiome Connect US – featuring an additional 60+ talks on key updates in microbiome drug development & manufacturing –, it’s the key forum for business networking and research connections, allowing you to assess how to take your research and establish efficacious, safe and viable solutions.

Who Will Be There

40%
Biotech
25%
Pharma & Investors
25%
Academia, Regulatory & Government Authorities
10%
Service Providers

Biotech

Pharma & Investors

Academia, Regulatory & Government Authorities

Service Providers

Past attendees

TESTIMONIALS

POSTER SUBMISSIONS

Are you looking to showcase your recent work to the phage community?

Our dedicated poster session is the perfect way to get your research noticed, ideal for PhD students or Post-Doctoral researchers. In order to present a poster, you need to register as a delegate. 

Please note that there is limited space available, and poster space is assigned on a first-come, first-served basis (subject to checks and successful registration). At the event, your presentation will be displayed in a dedicated poster area. The poster presentation session time of taking place is to be confirmed.

Posters should be sized A0 (841mm x 1189mm)

Poster abstract submission has now closed.

If you have any questions please contact [email protected]

40 %
Biotechs
25%
Pharma & Investors
25%
Academia, Regulatory & Government Authorities
10%
Service Providers

Speakers

 

Nancy Tawil

Chief Scientific Officer
Phagelux

Nancy Tawil, Mcb.A, M. Eng, Ph.D., is the Chief Scientific Officer at Phagelux Inc. and a Professor of Biomedical Engineering at Polytechnique Montreal where she oversees scientific research, product development, and clinical strategy.  Her research focuses on the development of novel heterofunctional materials and anti-infective treatments for multi-drug resistant infections. Her expertise and interests include drug delivery, phage science, polymer chemistry, and novel combination devices. Dr.

Nancy Tawil

Chief Scientific Officer
Phagelux

Nancy Tawil

Chief Scientific Officer
Phagelux

Nancy Tawil, Mcb.A, M. Eng, Ph.D., is the Chief Scientific Officer at Phagelux Inc. and a Professor of Biomedical Engineering at Polytechnique Montreal where she oversees scientific research, product development, and clinical strategy.  Her research focuses on the development of novel heterofunctional materials and anti-infective treatments for multi-drug resistant infections. Her expertise and interests include drug delivery, phage science, polymer chemistry, and novel combination devices. Dr. Tawil has over 15 years in phage research experience and is named inventor on multiple patents that aim to bridge the gap between phage science and technology.

 

Mimi Yen

CEO & Co-Founder
PhagePro Inc.

Dr. Yen is a 2018 MIT Technology Review Innovator Under 35 and a microbiologist with a global health and program management background. Since co-founding PhagePro, Dr. Yen has received numerous awards and won several startup competitions recognizing her innovative leadership in global health, such as the ASTMH Innovations Pitch Competition and LaunchBio's The Big Pitch. She has been selected for several fellowships, including the MassNextGen Fellowship for women-led early-stage life science businesses, The Capital Network Female Founder Fellowship, and the Henri Termeer Legacy Program.

Mimi Yen

CEO & Co-Founder
PhagePro Inc.

Mimi Yen

CEO & Co-Founder
PhagePro Inc.

Dr. Yen is a 2018 MIT Technology Review Innovator Under 35 and a microbiologist with a global health and program management background. Since co-founding PhagePro, Dr. Yen has received numerous awards and won several startup competitions recognizing her innovative leadership in global health, such as the ASTMH Innovations Pitch Competition and LaunchBio's The Big Pitch. She has been selected for several fellowships, including the MassNextGen Fellowship for women-led early-stage life science businesses, The Capital Network Female Founder Fellowship, and the Henri Termeer Legacy Program. An advocate for DEI in both biotech and global health communities, Dr. Yen strives to center the voices and the needs of the most marginalized.

 

Michele Wales

Chief Legal Officer
Adaptive Phage Therapeutics

Michele Wales

Chief Legal Officer
Adaptive Phage Therapeutics

Michele Wales

Chief Legal Officer
Adaptive Phage Therapeutics
 

Tobi Nagel

Founder
Phages for Global Health

Tobi Nagel

Founder
Phages for Global Health

Tobi Nagel

Founder
Phages for Global Health
 

Jen Schwartz

Vice President, Clinical Development
Intralytix

Jen Schwartz

Vice President, Clinical Development
Intralytix

Jen Schwartz

Vice President, Clinical Development
Intralytix
 

Dr Bob Blasdel

Research Director
Vesale Pharma

Dr Bob Blasdel

Research Director
Vesale Pharma

Dr Bob Blasdel

Research Director
Vesale Pharma
 

Dr David Pride

Associate Director of Microbiology
UC San Diego

Dr David Pride

Associate Director of Microbiology
UC San Diego

Dr David Pride

Associate Director of Microbiology
UC San Diego
 

Ella Balasa

Patient Advocate & Consultant

Ella Balasa

Patient Advocate & Consultant

Ella Balasa

Patient Advocate & Consultant
 

Dr Shawna McCallin

Clinical Coordinator
Balgirst University Hospital

Dr Shawna McCallin

Clinical Coordinator
Balgirst University Hospital

Dr Shawna McCallin

Clinical Coordinator
Balgirst University Hospital
 

Anna Jacobs

Biologist
BARDA

Anna Jacobs

Biologist
BARDA

Anna Jacobs

Biologist
BARDA
 

Dr Joe Campbell

Research Resources Project Officer
NIH (NIAID)

I am a program officer in the division of microbiology and infections diseases (DMID) in the National Institute of Allergies and Infectious Diseases (NIAID). My primary role is running the base contract under which our in vitro testing pre-clinical services are conducted (https://www.niaid.nih.gov/research/vitro-assessment-antimicrobial-activi...).

Dr Joe Campbell

Research Resources Project Officer
NIH (NIAID)

Dr Joe Campbell

Research Resources Project Officer
NIH (NIAID)

I am a program officer in the division of microbiology and infections diseases (DMID) in the National Institute of Allergies and Infectious Diseases (NIAID). My primary role is running the base contract under which our in vitro testing pre-clinical services are conducted (https://www.niaid.nih.gov/research/vitro-assessment-antimicrobial-activity-resources). In addition, I am involved in the running of contracts in our pre-clinical models of diseases base contract (https://www.niaid.nih.gov/research/pre-clinical-models-infectious-disease). Finally, I run DMID’s bacteriophage interest group.  The goal of this group is to work with the FDA and other federal agencies to promote the clinical use of bacteriophages.

 

Danish Malik

Senior Lecturer, Chemical Engineering Department
Loughborough University

Danish Malik

Senior Lecturer, Chemical Engineering Department
Loughborough University

Danish Malik

Senior Lecturer, Chemical Engineering Department
Loughborough University
 

Mikeljon Nikolich

Principal Investigator
Walter Reed Army Institute of Research

Mikeljon Nikolich

Principal Investigator
Walter Reed Army Institute of Research

Mikeljon Nikolich

Principal Investigator
Walter Reed Army Institute of Research
 

Dr. Cindy Fevre PhD

Director of R&D
Pherecydes Pharma

Dr. Cindy Fevre PhD

Director of R&D
Pherecydes Pharma

Dr. Cindy Fevre PhD

Director of R&D
Pherecydes Pharma
 

Dr Nick Conley

Vice President of Technology, Pharmaceutical Operations & Technology
Locus Biosciences

Dr.

Dr Nick Conley

Vice President of Technology, Pharmaceutical Operations & Technology
Locus Biosciences

Dr Nick Conley

Vice President of Technology, Pharmaceutical Operations & Technology
Locus Biosciences

Dr. Nick Conley is Principal Scientist for Locus Biosciences.  Before joining Locus in 2018, Nick was co-founder of EpiBiome, a South San Francisco-based precision microbiome engineering company that built the world’s first fully automated high-throughput phage discovery, characterization, and genomics platform, where he served in various roles, including CEO and Chief Science Officer.  During this time, the company gained admission into Illumina Accelerator, Johnson & Johnson Innovation’s JLABS, and Stanford-StartX; secured non-dilutive funding from the Bill & Melinda Gates Foundation and the US Department of Defense; established a top-3 pharma partnership; and raised more than $10 million dollars in financing.  Prior to EpiBiome, Nick was Staff Scientist at HGST, a Western Digital Company.  Nick completed a postdoc in Developmental Biology at Stanford University, and he holds a PhD and BS in Chemistry from Stanford University and The University of Texas at Austin, respectively.

 

 

Stephen Theriault

Chief Executive Officer & Chief Scientific Officer
Cytophage Technologies

Stephen Theriault

Chief Executive Officer & Chief Scientific Officer
Cytophage Technologies

Stephen Theriault

Chief Executive Officer & Chief Scientific Officer
Cytophage Technologies
 

Joel Berry

Director of Biology
Felix Biotechnologies

Joel Berry

Director of Biology
Felix Biotechnologies

Joel Berry

Director of Biology
Felix Biotechnologies

2022 Partners

Headline Partner

Platinum Partners

Gold Partners

Silver Partners

Event Partners

Lead Media Partner

Associate Media Partners

Venue Description

Venue

The Westin Boston Seaport District 425 Summer Street, Boston, MA, 02210

 

Partner With Us

Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact [email protected]

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]

View the 2022 Agenda

Find out what's in store this year at Phage Futures: USA 2022! Simply fill in this form to view our 2022 agenda immediately.

DOWNLOAD 2022 AGENDA

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us